Business Context and Reporting Period
This Form 8-K Current Report covers events occurring on May 31, 2023, for Avalo Therapeutics, Inc. (AVTX), a Delaware corporation. The filing primarily reports the entry into a material definitive agreement involving the exchange of equity securities.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The document focuses exclusively on a capital structure transaction.
- Transaction Volume: 1,300,000 shares of Common Stock exchanged.
- Instrument Issued: Pre-funded warrants (Exchange Warrants) to purchase 1,300,000 shares.
- Exercise Price: $0.001 per share.
- Counterparty: Entities affiliated with Venrock Healthcare Capital Partners.
Material Changes
The material change reported is the conversion of 1,300,000 shares of common stock held by Venrock-affiliated entities into pre-funded warrants. Key terms of this change include:
- Voting Rights: Holders of the Exchange Warrants do not have voting rights, except as required by Delaware law.
- Ownership Limitations: Warrants are not exercisable if the holder would beneficially own more than 9.99% of outstanding Common Stock. This limit can be increased to up to 19.99% with 61 days' notice.
- Regulatory Basis: The issuance relied on an exemption from registration under Section 3(a)(9) of the Securities Act of 1933.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of general business risks. It includes a standard disclaimer that representations and warranties in the Exchange Agreement were made solely for the benefit of the parties involved and should not be relied upon as accurately representing the Company's current affairs.
Investor Verification Checklist
- Verify the impact of the 1,300,000 share exchange on the total outstanding share count and potential dilution.
- Review the full text of the Exchange Agreement (Exhibit 10.1) and Form of Exchange Warrant (Exhibit 4.1) for specific covenants.
- Confirm the current beneficial ownership percentage of Venrock Healthcare Capital Partners to assess the 9.99% exercise limitation.
- Check subsequent filings for any updates on the exercise of these warrants or changes in the ownership cap.